Induction of Systemic Lupus Erythematosus with Tumor Necrosis Factor Blockers

Soforo, Ekaterina; Baumgartner, Manfred; Francis, Lisa; Allam, Fatme; Phillips, Paul E. M.; Perl, András

doi:10.3899/jrheum.081312

Cited by 42 publications

(34 citation statements)

References 11 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In accordance with this finding, TNF-null mice developed severe EAE (40). TNF inhibitors sometimes induce a lupus-like syndrome in the clinical setting (41). In an animal model, TNF-null (NZB ϫ NZW)F 1 mice developed lupus nephritis (42), and injection of high doses of TNF delayed disease onset (43).…”

Section: Il-1 and Tnf␣ Blockade Treatment Of Pm In Micementioning

confidence: 57%

Interleukin‐1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice

Sugihara¹,

Okiyama²,

Watanabe³

et al. 2012

Arthritis & Rheumatism

View full text Add to dashboard Cite

Polymyositis (PM) is a chronic autoimmune inflammatory myopathy affecting striated muscles (1). An accumulated body of evidence supports the notion that the pathology of PM is driven by cytotoxic CD8 T cells (2-7), but the event that initiates the inflammatory processes has not been identified. Currently, patients with PM are treated primarily with nonspecific immunosuppressants, including high-dose corticosteroids, methotrexate, and/or other small-molecule immunosuppressants. Because the administration of therapeutic agents can elicit a wide variety of adverse reactions, treatments that address the specific pathology of PM need to be developed.In the development of new therapeutic approaches to human diseases, animal models have served as a means with which to identify therapeutic targets and to test the effect of new treatments (8-11). Despite the known limitations, experiments in animals with collagen-induced arthritis (CIA) have facilitated development of new treatments for rheumatoid arthritis (RA). Treatment approaches such as blockade of interleukin-1 (IL-1), tumor necrosis factor ␣ (TNF␣), and IL-6 have had an enormous effect in modulating the disease course of RA (12-15).However, in myositis research, no appropriate

show abstract

Section: Il-1 and Tnf␣ Blockade Treatment Of Pm In Micementioning

confidence: 57%

Interleukin‐1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice

Sugihara¹,

Okiyama²,

Watanabe³

et al. 2012

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…We would emphasize the significant difference between these 2 cases and the cases described by Soforo, et al 1 . In those cases, full-blown active systemic lupus erythematosus (SLE) fulfilling 4 or more American College of Rheumatology criteria 2 for diagnosis of SLE was demonstrated.…”

Section: To the Editormentioning

confidence: 65%

Dr. N. Jacob and Dr. C.O. Jacob reply

Jacob¹,

Jacob²

2011

J Rheumatol

View full text Add to dashboard Cite

“…We read with interest the recent letter 1 and editorial 2 discussing anti-tumor necrosis factor (anti-TNF)-induced lupus requiring cessation of therapy for disease resolution. A lack of published experience of successful TNF inhibitor switching (8 total cases in the literature) causes concern for rheumatologists faced with this clinical scenario.…”

Section: To the Editormentioning

confidence: 99%